Journal of the Korean Medical Association10.5124/jkma.2023.66.2.86202366286-90How do we trade off benefits and harms of anticancer drugs for advanced cancer patients?Do Yeun Kim,,
BMJ Open10.1136/bmjopen-2020-03832220201012e038322How do cancer screening guidelines trade off benefits versus harms and burdens of screening? A systematic surveyLinan Zeng, Lise Mørkved Helsingen, Fernando Kenji Nampo, Yuting Wang, Liang Yao, Reed Alexander Siemieniuk, Michael Bretthauer, Gordon H Guyatt
BMJ10.1136/bmj.p6232023p623Communicating the benefits and harms of anticancer drugsTimothy Feeney, Tiago Villanueva, Amy Price,
Drugs10.1007/s40265-013-0028-02013734293-301LDL Cholesterol Goals in High-Risk Patients: How Low Do We Go and How Do We Get There?Joost Besseling, Julian van Capelleveen, John J. P. Kastelein, G. Kees Hovingh,,
EClinicalMedicine10.1016/j.eclinm.2021.101130202140101130Risks and benefits of anticancer drugs in advanced cancer patients: A systematic review and meta-analysisCamille Moreau Bachelard, Elodie Coquan, Pauline du Rusquec, Xavier Paoletti, Christophe Le Tourneau,
European Journal of Cancer10.1016/s0959-8049(14)50044-5201450S1244: The benefits of precision medicine will require us to examine both what we do and how we do itS. Friend,
Compensation & Benefits Review10.1177/08863687198959342019514144-161Gender Pay Gaps, the U.K. Experience: How Do We Close Them, How Do We Bring Research Into Practice?Duncan Brown,,
Internal Medicine Journal10.1111/imj.128022015458834-842Weighing up the benefits and harms of a new anti-cancer drug: a survey of Australian oncologistsL. Chim, G. Salkeld, M. R. Stockler, L. Mileshkin,
European Journal of Cancer10.1016/s0959-8049(01)82059-1200137S433-S434How do we increase quality of life for patients with dyspnoea suffering from advanced cancer, by using patient educationJ.B. Erntgaard, K. Gudmundsen, K. Bjørum,
Internal Medicine Journal10.1111/j.1445-5994.2012.02751.x201242111224-1229Access to anticancer drugs: many evidence-based treatments are off-label and unfunded by the Pharmaceutical Benefits SchemeJ. D. Mellor, P. Van Koeverden, S. W. K. Yip, A. Thakerar, S. W. Kirsa, M. Michael,